Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models
American Journal of Physiology-Gastrointestinal and Liver Physiology · 2024
DOI: 10.1152/ajpgi.00022.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, 2024. Verfasst von Emelie Öhnstedt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Ilya Pharma AB, Uppsala, Sweden. Hauptthemen laut MEDLINE: Colitis, Limosilactobacillus reuteri, Chemokine CXCL12, Dextran Sulfate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ilya Pharma AB, BioX grant from STUND to Ilya Pharma, Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation).
Abstract (Originalsprache)
Colitis symptoms are efficiently reduced by peroral administration of probiotic bacteria genetically modified to deliver CXCL12 locally to the inflamed intestine in several mouse models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ilya Pharma AB, Uppsala, Sweden.
- Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
- Department of Molecular Sciences, Swedish University of Agriculture, Uppsala, Sweden.
- The Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Emelie Öhnstedt, Evelina Vågesjö, Mia Phillipson
Förderung
- Ilya Pharma AB
- BioX grant from STUND to Ilya Pharma
- Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)
Zitieren
APA
Öhnstedt, E., Doñas, C., Parv, K., Pang, Y., Lofton Tomenius, H., Carrasco López, M., Gannavarapu, V. R., Choi, J., Ovezik, M., Frank, P., Jorvid, M., Roos, S., Vågesjö, E., & Phillipson, M. (2024). Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00022.2024
Vancouver
Öhnstedt E, Doñas C, Parv K, Pang Y, Lofton Tomenius H, Carrasco López M, et al. Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2024. doi:10.1152/ajpgi.00022.2024
BibTeX
@article{hnstedt2024,
author = {Öhnstedt, Emelie and Doñas, Cristian and Parv, Kristel and Pang, Yanhong and Lofton Tomenius, Hava and Carrasco López, Macarena and Gannavarapu, Venkata Ram and Choi, Jacqueline and Ovezik, Maria and Frank, Peter and Jorvid, Margareth and Roos, Stefan and Vågesjö, Evelina and Phillipson, Mia},
title = {Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models},
journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
year = {2024},
doi = {10.1152/ajpgi.00022.2024}
}
EUVIMED